Nebulized Lidocaine in COVID-19, An Hypothesis
Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Ali, Ziad A. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020transfer abstract |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors - Fan, Ya-Meng ELSEVIER, 2017transfer abstract, Burlington, Mass |
|---|---|
| Übergeordnetes Werk: |
volume:144 ; year:2020 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.mehy.2020.109947 |
|---|
| Katalog-ID: |
ELV05211547X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV05211547X | ||
| 003 | DE-627 | ||
| 005 | 20230626032850.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210910s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mehy.2020.109947 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001322.pica |
| 035 | |a (DE-627)ELV05211547X | ||
| 035 | |a (ELSEVIER)S0306-9877(20)31293-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Ali, Ziad A. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nebulized Lidocaine in COVID-19, An Hypothesis |
| 264 | 1 | |c 2020transfer abstract | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients’ lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted. | ||
| 520 | |a Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients’ lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted. | ||
| 650 | 7 | |a COVID-19 |2 Elsevier | |
| 650 | 7 | |a SARS-CoV-2 |2 Elsevier | |
| 650 | 7 | |a Cytokine-storm |2 Elsevier | |
| 650 | 7 | |a Anti-inflammatories |2 Elsevier | |
| 650 | 7 | |a Lidocaine |2 Elsevier | |
| 700 | 1 | |a El-Mallakh, Rif S. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Harcourt |a Fan, Ya-Meng ELSEVIER |t Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors |d 2017transfer abstract |g Burlington, Mass |w (DE-627)ELV015462293 |
| 773 | 1 | 8 | |g volume:144 |g year:2020 |g pages:0 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.mehy.2020.109947 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.00 |j Medizin: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 144 |j 2020 |h 0 | ||
| author_variant |
z a a za zaa |
|---|---|
| matchkey_str |
aliziadaelmallakhrifs:2020----:euieldcienoi1 |
| hierarchy_sort_str |
2020transfer abstract |
| bklnumber |
44.00 |
| publishDate |
2020 |
| allfields |
10.1016/j.mehy.2020.109947 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001322.pica (DE-627)ELV05211547X (ELSEVIER)S0306-9877(20)31293-7 DE-627 ger DE-627 rakwb eng 540 VZ 610 VZ 44.00 bkl Ali, Ziad A. verfasserin aut Nebulized Lidocaine in COVID-19, An Hypothesis 2020transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients’ lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted. Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients’ lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted. COVID-19 Elsevier SARS-CoV-2 Elsevier Cytokine-storm Elsevier Anti-inflammatories Elsevier Lidocaine Elsevier El-Mallakh, Rif S. oth Enthalten in Harcourt Fan, Ya-Meng ELSEVIER Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors 2017transfer abstract Burlington, Mass (DE-627)ELV015462293 volume:144 year:2020 pages:0 https://doi.org/10.1016/j.mehy.2020.109947 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.00 Medizin: Allgemeines VZ AR 144 2020 0 |
| spelling |
10.1016/j.mehy.2020.109947 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001322.pica (DE-627)ELV05211547X (ELSEVIER)S0306-9877(20)31293-7 DE-627 ger DE-627 rakwb eng 540 VZ 610 VZ 44.00 bkl Ali, Ziad A. verfasserin aut Nebulized Lidocaine in COVID-19, An Hypothesis 2020transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients’ lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted. Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients’ lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted. COVID-19 Elsevier SARS-CoV-2 Elsevier Cytokine-storm Elsevier Anti-inflammatories Elsevier Lidocaine Elsevier El-Mallakh, Rif S. oth Enthalten in Harcourt Fan, Ya-Meng ELSEVIER Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors 2017transfer abstract Burlington, Mass (DE-627)ELV015462293 volume:144 year:2020 pages:0 https://doi.org/10.1016/j.mehy.2020.109947 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.00 Medizin: Allgemeines VZ AR 144 2020 0 |
| allfields_unstemmed |
10.1016/j.mehy.2020.109947 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001322.pica (DE-627)ELV05211547X (ELSEVIER)S0306-9877(20)31293-7 DE-627 ger DE-627 rakwb eng 540 VZ 610 VZ 44.00 bkl Ali, Ziad A. verfasserin aut Nebulized Lidocaine in COVID-19, An Hypothesis 2020transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients’ lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted. Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients’ lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted. COVID-19 Elsevier SARS-CoV-2 Elsevier Cytokine-storm Elsevier Anti-inflammatories Elsevier Lidocaine Elsevier El-Mallakh, Rif S. oth Enthalten in Harcourt Fan, Ya-Meng ELSEVIER Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors 2017transfer abstract Burlington, Mass (DE-627)ELV015462293 volume:144 year:2020 pages:0 https://doi.org/10.1016/j.mehy.2020.109947 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.00 Medizin: Allgemeines VZ AR 144 2020 0 |
| allfieldsGer |
10.1016/j.mehy.2020.109947 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001322.pica (DE-627)ELV05211547X (ELSEVIER)S0306-9877(20)31293-7 DE-627 ger DE-627 rakwb eng 540 VZ 610 VZ 44.00 bkl Ali, Ziad A. verfasserin aut Nebulized Lidocaine in COVID-19, An Hypothesis 2020transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients’ lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted. Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients’ lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted. COVID-19 Elsevier SARS-CoV-2 Elsevier Cytokine-storm Elsevier Anti-inflammatories Elsevier Lidocaine Elsevier El-Mallakh, Rif S. oth Enthalten in Harcourt Fan, Ya-Meng ELSEVIER Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors 2017transfer abstract Burlington, Mass (DE-627)ELV015462293 volume:144 year:2020 pages:0 https://doi.org/10.1016/j.mehy.2020.109947 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.00 Medizin: Allgemeines VZ AR 144 2020 0 |
| allfieldsSound |
10.1016/j.mehy.2020.109947 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001322.pica (DE-627)ELV05211547X (ELSEVIER)S0306-9877(20)31293-7 DE-627 ger DE-627 rakwb eng 540 VZ 610 VZ 44.00 bkl Ali, Ziad A. verfasserin aut Nebulized Lidocaine in COVID-19, An Hypothesis 2020transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients’ lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted. Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients’ lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted. COVID-19 Elsevier SARS-CoV-2 Elsevier Cytokine-storm Elsevier Anti-inflammatories Elsevier Lidocaine Elsevier El-Mallakh, Rif S. oth Enthalten in Harcourt Fan, Ya-Meng ELSEVIER Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors 2017transfer abstract Burlington, Mass (DE-627)ELV015462293 volume:144 year:2020 pages:0 https://doi.org/10.1016/j.mehy.2020.109947 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.00 Medizin: Allgemeines VZ AR 144 2020 0 |
| language |
English |
| source |
Enthalten in Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors Burlington, Mass volume:144 year:2020 pages:0 |
| sourceStr |
Enthalten in Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors Burlington, Mass volume:144 year:2020 pages:0 |
| format_phy_str_mv |
Article |
| bklname |
Medizin: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
COVID-19 SARS-CoV-2 Cytokine-storm Anti-inflammatories Lidocaine |
| dewey-raw |
540 |
| isfreeaccess_bool |
false |
| container_title |
Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors |
| authorswithroles_txt_mv |
Ali, Ziad A. @@aut@@ El-Mallakh, Rif S. @@oth@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
ELV015462293 |
| dewey-sort |
3540 |
| id |
ELV05211547X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV05211547X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626032850.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.mehy.2020.109947</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001322.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV05211547X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0306-9877(20)31293-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ali, Ziad A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Nebulized Lidocaine in COVID-19, An Hypothesis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients’ lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients’ lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">COVID-19</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SARS-CoV-2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cytokine-storm</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anti-inflammatories</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lidocaine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">El-Mallakh, Rif S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Harcourt</subfield><subfield code="a">Fan, Ya-Meng ELSEVIER</subfield><subfield code="t">Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors</subfield><subfield code="d">2017transfer abstract</subfield><subfield code="g">Burlington, Mass</subfield><subfield code="w">(DE-627)ELV015462293</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:144</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.mehy.2020.109947</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.00</subfield><subfield code="j">Medizin: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">144</subfield><subfield code="j">2020</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| author |
Ali, Ziad A. |
| spellingShingle |
Ali, Ziad A. ddc 540 ddc 610 bkl 44.00 Elsevier COVID-19 Elsevier SARS-CoV-2 Elsevier Cytokine-storm Elsevier Anti-inflammatories Elsevier Lidocaine Nebulized Lidocaine in COVID-19, An Hypothesis |
| authorStr |
Ali, Ziad A. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV015462293 |
| format |
electronic Article |
| dewey-ones |
540 - Chemistry & allied sciences 610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
540 VZ 610 VZ 44.00 bkl Nebulized Lidocaine in COVID-19, An Hypothesis COVID-19 Elsevier SARS-CoV-2 Elsevier Cytokine-storm Elsevier Anti-inflammatories Elsevier Lidocaine Elsevier |
| topic |
ddc 540 ddc 610 bkl 44.00 Elsevier COVID-19 Elsevier SARS-CoV-2 Elsevier Cytokine-storm Elsevier Anti-inflammatories Elsevier Lidocaine |
| topic_unstemmed |
ddc 540 ddc 610 bkl 44.00 Elsevier COVID-19 Elsevier SARS-CoV-2 Elsevier Cytokine-storm Elsevier Anti-inflammatories Elsevier Lidocaine |
| topic_browse |
ddc 540 ddc 610 bkl 44.00 Elsevier COVID-19 Elsevier SARS-CoV-2 Elsevier Cytokine-storm Elsevier Anti-inflammatories Elsevier Lidocaine |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
r s e m rse rsem |
| hierarchy_parent_title |
Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors |
| hierarchy_parent_id |
ELV015462293 |
| dewey-tens |
540 - Chemistry 610 - Medicine & health |
| hierarchy_top_title |
Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV015462293 |
| title |
Nebulized Lidocaine in COVID-19, An Hypothesis |
| ctrlnum |
(DE-627)ELV05211547X (ELSEVIER)S0306-9877(20)31293-7 |
| title_full |
Nebulized Lidocaine in COVID-19, An Hypothesis |
| author_sort |
Ali, Ziad A. |
| journal |
Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors |
| journalStr |
Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science 600 - Technology |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Ali, Ziad A. |
| container_volume |
144 |
| class |
540 VZ 610 VZ 44.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Ali, Ziad A. |
| doi_str_mv |
10.1016/j.mehy.2020.109947 |
| dewey-full |
540 610 |
| title_sort |
nebulized lidocaine in covid-19, an hypothesis |
| title_auth |
Nebulized Lidocaine in COVID-19, An Hypothesis |
| abstract |
Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients’ lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted. |
| abstractGer |
Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients’ lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted. |
| abstract_unstemmed |
Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients’ lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Nebulized Lidocaine in COVID-19, An Hypothesis |
| url |
https://doi.org/10.1016/j.mehy.2020.109947 |
| remote_bool |
true |
| author2 |
El-Mallakh, Rif S. |
| author2Str |
El-Mallakh, Rif S. |
| ppnlink |
ELV015462293 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth |
| doi_str |
10.1016/j.mehy.2020.109947 |
| up_date |
2024-07-06T22:08:41.662Z |
| _version_ |
1803869195246501888 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV05211547X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626032850.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.mehy.2020.109947</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001322.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV05211547X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0306-9877(20)31293-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ali, Ziad A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Nebulized Lidocaine in COVID-19, An Hypothesis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients’ lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients’ lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">COVID-19</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SARS-CoV-2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cytokine-storm</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anti-inflammatories</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lidocaine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">El-Mallakh, Rif S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Harcourt</subfield><subfield code="a">Fan, Ya-Meng ELSEVIER</subfield><subfield code="t">Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors</subfield><subfield code="d">2017transfer abstract</subfield><subfield code="g">Burlington, Mass</subfield><subfield code="w">(DE-627)ELV015462293</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:144</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.mehy.2020.109947</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.00</subfield><subfield code="j">Medizin: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">144</subfield><subfield code="j">2020</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.39935 |